Literature DB >> 12962009

Molecular targets in cancer therapy.

Danielle M Gale1.   

Abstract

OBJECTIVES: To review selected pharmacologic agents that target key cellular processes along with their mechanisms of action and adverse events. Nursing implications including what patients and families need to know, administration issues, and management of common toxicities will be reviewed. DATA SOURCES: Research articles, clinical trials, abstracts, and book chapters.
CONCLUSION: Knowledge of complex biology and biochemistry regulating normal and abnormal cellular function obtained over the past 30 years is starting to be used clinically for new therapies to treat cancer. By targeting what makes cancer unique, these therapies are able to spare more healthy or normal cells than the standard treatments, such as radiation and chemotherapy. Several molecular targeting agents are now in use and even more are under study as cancer treatments. IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses must understand the principles underlying targeted treatments and their potential benefits to provide adequate patient education and care.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12962009     DOI: 10.1016/s0749-2081(03)00047-0

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  3 in total

1.  Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education.

Authors:  David M Plevin; Helena M Ward; Michael B Ward; Michael J Sorich; Ross A McKinnon
Journal:  Am J Pharm Educ       Date:  2010-11-10       Impact factor: 2.047

2.  Modified synthesis of erlotinib hydrochloride.

Authors:  Leila Barghi; Ayuob Aghanejad; Hadi Valizadeh; Jaleh Barar; Davoud Asgari
Journal:  Adv Pharm Bull       Date:  2012-05-05

3.  Uptake of the carborane derivative of cholesteryl ester by glioma cancer cells is mediated through LDL receptors.

Authors:  Guangliang Pan; Svein Oie; D Robert Lu
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.